944 results on '"Loriot Y"'
Search Results
2. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma
3. TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes
4. Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201
5. Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer
6. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial
7. Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma
8. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
9. French AFU Cancer Committee Guidelines – Update 2022–2024: Upper urinary tract urothelial cancer (UTUC)
10. French AFU Cancer Committee Guidelines - Update 2022-2024: Non-muscle-invasive bladder cancer (NMIBC)
11. French AFU Cancer Committee Guidelines – Update 2022–2024: Muscle-Invasive Bladder Cancer (MIBC)
12. Recommandations du Comité de cancérologie de l’Association Française d’Urologie (CC-AFU) pour la bonne pratique des instillations intravésicales de mitomycine C, d’épirubicine et de BCG pour le traitement des tumeurs de la vessie n’infiltrant pas le muscle (TVNIM)
13. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
14. Recommandations des Comités de cancérologie (CC-AFU) et d’infectiologie (CI-AFU) de l’Association française d’urologie pour la prise en charge effets indésirables et complications du BCG
15. SOGUG-NEOWIN: A Phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of Erdafitinib (ERDA) monotherapy and ERDA and Cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with Muscle-Invasive Bladder Cancer (MIBC) whose tumours express FGFR gene alterations
16. Phase 3 study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001; trial in progress)
17. SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy
18. Safety and efficacy of antibody drug conjugates in older patients with solid tumors
19. P1.23-07 Clinical Impact of Clonal Hematopoiesis in Patients with Advanced Non-small Cell Lung Cancer: Results of the CHIC Study
20. Pemigatinib for Metastatic or Surgically Unresectable Urothelial Carcinoma With FGF/FGFR Genomic Alterations: Final Results From FIGHT-201
21. ANTIBODY DRUG CONJUGATES IN OLDER PATIENTS: STATE OF THE ART
22. Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
23. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
24. Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases
25. Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer
26. Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study
27. Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study
28. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
29. 5O Deciphering resistance mechanisms in cancer: Insights from the final report of MATCH-R study with focus on molecular drivers
30. 41P BRCA2 pathogenic variant (PV): A novel agnostic biomarker for immune checkpoint blockers (ICB)?
31. 85P Stereotactic radiotherapy improves disease control in oligoprogressive patients included in early clinical trials
32. 2P Outcomes of patients with gynecological tumors harboring HER2 defects: A single center study based on Gustave Roussy cancer center’s molecular program
33. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment
34. Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)
35. 176P Phase I study of INCB106385 alone or in combination with immunotherapy in advanced solid tumors
36. EE301 Cost-Effectiveness Analysis of Avelumab Plus Best Supportive Care (BSC) As First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma (La/mUC) in France
37. Toxicités et complications chirurgicales du Pembrolizumab administré avant cystectomie chez les patients atteints de cancer de la vessie infiltrant le muscle : résultats de l’essai pandore
38. Trial In Progress: DISCUS: A randomized phase II study comparing 3 vs. 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer
39. 34P Gustave Roussy Match-R study: A descriptive analysis of the molecular target population
40. Detection of myeloid malignancies through cfDNA profiling in patients with advanced stage cancer
41. 129P Molecular screening and early phase trial inclusion for head and neck squamous cell carcinoma patients
42. High prevalence of Clonal Hematopoiesis of indeterminate potential (CHIP) associated mutations in elderly patients with solid tumors
43. 1405P Circulating tumor DNA in advanced prostate cancer: Focus on high blood tumor mutational burden (h-bTMB)
44. 1742P Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC)
45. 1752P Post hoc analysis of pembrolizumab efficacy in potentially platinum ineligible patients with urothelial carcinoma enrolled in KEYNOTE-052 and LEAP-011
46. 1779TiP Phase II clinical study evaluating the efficacy and safety of disitamab vedotin in patients (pts) with HER2-expressing urothelial carcinoma (RC48G001)
47. 461P Overview of patients inclusions and outcomes into modern phase I trials at Gustave Roussy over the last 5 years, OVATION study
48. 1380P High Sonic Hedgehog (HH) signalling activity, low androgen receptor activity and clonal evolution are associated with resistance to androgen-receptor axis inhibitors in patients with metastatic prostate cancer
49. 1757P Preliminary results from AVENANCE, an ongoing, noninterventional real-world, ambispective study of avelumab first-line (1L) maintenance treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC)
50. 1760P Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Results from patients with ≥12 mo of treatment in JAVELIN Bladder 100
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.